Calls
7
#992
Alpha Score 26.8
u/board_meeting45
Reddit r/ValueInvesting
Win Rate
0.0%
return
-2.8%
Loading charts...
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Sep 09
$8.80
-0.8%
Arvinas is assigned a 15% weight in the author's AI-screened biotech portfolio, based on clinical stage, approval probability, market size and cash runway criteria. The bet is on the company's targeted protein degradation pipeline reaching key milestones. Main risk is the AI analysis overlooking bear-case assumptions and the concentrated portfolio construction.
Pharma & Biotech
Long
Sep 09
$99.00
-2.6%
BioNTech receives a 20% weight in the author's AI-generated biotech portfolio, screened on regulatory progress, clinical trial stages, approval probabilities, market size, cash reserves and financial runway. The position reflects conviction in the pipeline and balance sheet strength. Main risk is the concentrated sizing and reliance on AI-derived assumptions.
Pharma & Biotech
Long
Sep 09
$53.66
-3.3%
CRISPR Therapeutics receives a 15% weight in the author's AI-screened biotech portfolio, based on clinical trial stages, estimated approval probabilities, market size and cash reserves. The bet is on gene-editing pipeline commercialization. Main risk is the AI analysis missing bear-case assumptions and the concentrated sizing.
Pharma & Biotech
Long
Sep 09
$13.59
-3.4%
HUTCHMED is given a 15% weight in the author's AI-generated biotech portfolio, screened for regulatory progress, trial stage, approval probability, market size and balance-sheet strength. The thesis is a concentrated bet on the company's drug pipeline and financial runway. Main risk is the AI-derived assumptions and portfolio concentration.
Pharma & Biotech
Long
Sep 09
$34.47
-2.6%
Author's AI-driven screen assigns Immunocore the largest 25% weight in a hypothetical $100k biotech portfolio, based on criteria including clinical trial stage, estimated approval probabilities, market size, cash reserves and runway to next milestone. The thesis is a concentrated bet on the company's pipeline succeeding. Main risk is the concentration itself and the AI analysis potentially overlooking bear-case assumptions.
Pharma & Biotech
Long
Sep 09
$19.90
-3.6%
Legend Biotech is assigned a 5% weight in the author's AI-generated biotech portfolio, screened on regulatory progress, clinical stage, approval probability, market size and financial runway. The small weight reflects lower conviction relative to the top five positions. Main risk is the AI-derived assumptions and portfolio concentration.
Pharma & Biotech
Long
Sep 09
$12.30
-3.2%
Intellia Therapeutics receives a 5% weight in the author's AI-screened biotech portfolio, based on clinical trial stages, approval probabilities, market size and cash reserves. The small allocation reflects lower conviction than the top five names. Main risk is the AI analysis overlooking bear-case assumptions and the concentrated portfolio construction.
Pharma & Biotech
Showing 7 of 7 calls · sorted by mentions
Choose a mentions count to open ticker posts.
u/board_meeting45 has 7 trade ideas tracked on Buzzberg across 7 tickers since September 2026. Ranked #992 on the Buzzberg Alpha leaderboard. Most covered: CRSP, NTLA, BNTX.
